Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

LEUVEN, Belgium and LUND, Sweden, February 23 /PRNewswire-FirstCall/ --

- Trial to Assess the Benefits of Partial Factor VIII Inhibition in Patients Undergoing Knee Replacement Surgery

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.

TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients across 36 centers mainly in Central Europe. The primary endpoint is the safety and efficacy of the three
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  Propanc Health Group Corporation (OTCBB: PPCH) is ... development of cancer treatments for patients with pancreatic ... PRP, a patented formulation consisting of two pro-enzymes, ... the enzyme amylase designed to synergistically enhance anti-cancer ... anti-cancer agents working in combination with pro-enzymes, which ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced that it will report ... May 7, 2015 after the close of the market. ... for 4.30 pm ET (1.30 pm PT) to discuss ... conference call will be webcast over the internet and ... media and the general public. To access the webcast ...
(Date:4/22/2015)... Steep Hill, the industry leader in ... has opened an investment round of $5 million ... common stock investment round will be offered through ... to encourage funding of small businesses by easing ... largely relied on friends and family, venture capitalists ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... April 10 Dedicating this year,s,Venture Forum to the ... announced a partnership in developing and producing the 2008,Life ... and,innovative seed and early-stage life sciences companies from the ... Forum will take place on,May 30, 2008, at the ...
... Medicsight PLC, a,subsidiary of MGT Capital Investments, ... in the development of Computer-Aided Detection (CAD) and ... and diagnosis of,disease, today announced that it has ... Administration ("SFDA") for its MedicRead Colon,workstation. Medicsight will ...
... -, PRINCETON, N.J., April 10, 2008 ... production,company, today announced that it has entered into ... According to the,agreement, Laureate will produce Alopexx,s mAb ... for use in clinical trials, and later,for commercial ...
Cached Biology Technology:Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 2Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum 3Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 2Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation 3Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 2Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... BURNABY, Canada , April 17, 2015 /PRNewswire/ ... projects, growing security concerns, and technological advancement to ... Arabia until 2020   ... " Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric ... is projected to register growth at CAGR ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 22, 2011) - An animal,s behavior is probably ... alike. Its behavior involves processes internal to the animalgenetics, ... and social surroundings. According to the book,s authors, "Animal ... is sparked when neurons fire in response to stimuli ...
... available in German . The ... career researchers in Germany have been chosen. The selection ... Foundation) and the German Federal Ministry of Education and ... male researchers for the Heinz Maier-Leibnitz Prize 2011. The ...
... Research Council (BBSRC) announces the signing of a Memorandum of ... and Technology (MOST) in Vietnam. This heralds the start of ... tolerance in the world,s most important staple food in the ... Funds of up to 350K are being made available by ...
Cached Biology News:New book on animal behavior provides integrated view 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 2Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 3Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 4Heinz Maier-Leibnitz Prizes 2011: Recognition and incentive for early career researchers 5UK-Vietnam collaboration to improve world's most important staple food 2UK-Vietnam collaboration to improve world's most important staple food 3
...
Liquid. Phycoerythrin conjugate is in PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide....
... Supercoiled DNA Ladder is suitable ... 2 to 16 kb by ... bands can be visualized by ... also be detected on Southern ...
...
Biology Products: